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Comparison of fixed-dose weight-adjusted unfractionated heparin and
low-molecular-weight heparin for acute treatment of venous
thromboembolism
Kearon C, Ginsberg JS, Julian JA; and the Fixed-Dose Heparin Investiga-
tors. JAMA 2006;296:936-42.
Conclusion: Low-molecular-weight heparin and fixed-dose subcuta-
neous unfractionated heparin are equally as effective for outpatient treat-
ment of acute venous thromboembolism (VTE).
Summary: The authors sought to determine if weight-adjusted, fixed-
dose subcutaneous unfractionated heparin would be as effective and safe as
low-molecular-weight heparin in the treatment of VTE. This was a random-
ized, adjudicated, blinded, open-labeled, noninferiority trial. There were
708 patients, all 18 years of age, and all had acute VTE. The study was
conducted in six university-affiliated medical centers in New Zealand and
Canada. The study ran from September 1998 through February 2004.
Patients treated with weight-adjusted unfractionated heparin (n 
345) received an initial dose of 333 U/kg, followed by fixed doses of 250
U/kg every 12 hours. Patients treated with low-molecular-weight heparin
(n  352) received either dalteparin or enoxaparin. Low-molecular-weight
heparin was administered subcutaneously at a dose of 100 IU/kg every 12
hours. Patients treated with either unfractionated or low-molecular-weight
heparin could be treated as outpatients. Both forms of treatment overlapped
with warfarin therapy for 3 months. The principal end point of the study was
recurrent VTE or major bleeding within 10 days.
A study drug was given for a mean of 6.6 days in the unfractionated
heparin group and a mean of 7.1 days in the low-molecular-weight heparin
group. There were 12 episodes (3.4%) of recurrent VTE in the low-
molecular-weight heparin group and 13 episodes (3.8%) in the unfraction-
ated heparin group. This was an absolute difference of 0.4% (95% confidence
interval, 2.6% to 3.3%). Equal amounts of major bleeding occurred
between the two groups, with major bleeding in the first 10 days of
treatment in four patients (1.1%) in the unfractionated heparin group and in
five patients (1.4%) in the low-molecular-weight heparin group (95% confi-
dence interval, 2.3% to 1.7%). Treatment was administered outside of a
hospital in 68% of the patients treated with low-molecular-weight heparin
and 72% of the patients treated with weight-adjusted unfractionated
heparin.
In patients treated with unfractionated heparin, activated partial
thromboplastin time (aPTT) was measured halfway between injections at a
mean of 2.8 days after starting therapy. The aPTT values were 60
seconds in 39 patients, 60 to 85 seconds in 37, and 85 seconds in 121
patients. Levels of aPTT were not associated with recurrent VTE or
major bleeding.
Comment: The data suggest unfractionated heparin administered
subcutaneously on a weight-based dosage regimen and low-molecular-
weight heparin can provide equal protection against recurrent VTE in
patients with acute VTE. The study has significant implications for all
patients who are unable to afford the cost of low-molecular-weight heparin
as an outpatient. Perhaps such patients can be treated at home with weight-
based, fixed doses of unfractionated heparin? This will remove a potential
barrier to outpatient treatment of acute VTE in patients who cannot afford
the cost of low-molecular-weight heparin as an outpatient.
Femoral vessel injuries: analysis of factors predictive of outcomes
Asensio JA, Kuncir EJ, Garcia-Nunez LN, et al. J Am Coll Surg 2006;2003:
512-20.
Conclusion: There is both a high survival and complication rate for
treatment of femoral vessel injuries.
Summary: This was a retrospective study of patients admitted during a
132-month period (January 1, 1992 throughDecember 31, 2002) at a large
level 1 urban trauma center. Univariant and multivariant analysis were used
to determine predictors of outcome after femoral vessel injury.
There were 204 patients with 298 vessel injuries consisting of 204
arterial and 94 venous injuries. Mean patient age was 29  13 years. Mean
injury severity score was 17  8. Eighty-six percent of injuries (n  176)
were penetrating, and 14% (n  28) were blunt injuries.
Numerous techniques were used for both arterial and venous repairs. In
arterial repairs, reverse saphenous vein grafts were used in 53%. Primary
repair of the injury was performed in 26%. A polytetrafluoroethylene graft
was placed in 10.2%. The femoral vessel was ligated in 6.4%. With respect to
femoral venous injuries, 52% were ligated, 44% underwent primary repair,
and 4% underwent bypass. Twenty-seven percent of the patients underwent
fasciotomy of the calf, and 12% underwent fasciotomy of the thigh. There
were six acute amputations and no delayed amputations. Overall survival was
91%; when emergency department thoracotomy deaths were excluded,
adjusted survival was 95%.
Complications occurred in 47 patients (23%). The most common
complication was wound infection (n 31), followed by venous thrombosis
(n  6). Arterial thrombosis occurred in only one patient. Predictors of
postoperative complication included interoperative hypertension, arterial
injury, long bone facture, and thoracic injury. Predictors of mortality were
age45 years, injury severity score25, common femoral artery injury, and
the combination of venous and abdominal injuries.
Comment:Reports such as this do not provide much in the way of new
insights. Predictors of mortality, complications, and the types of complica-
tions are what one would expect. It is interesting, however, to note the very
high survival rate for patients with such injuries treated in a level 1 trauma
center.
Plasma d-lactate as a potential early marker for colon ischaemia after
open aortic reconstruction
Assadian A, Assadian O, Senekowitsch C, et al. Eur J Vasc Endovasc Surg
2006;31:470-4.
Conclusion: Plasma d-lactate levels are a useful marker to detect
ischemic colitis after aortic surgery.
Summary: Ischemic colitis after aortic surgery has mortality rates of up
to 90%. Ischemic colitis must currently be diagnosed with endoscopic
techniques. D-lactate and bacterial endotoxin have been reported in animal
studies as markers of breakdown of the mucosal barrier after intestinal
hypoperfusion. The authors sought to evaluate potential efficacy of these
markers in clinical practice after aortic surgery. This was a prospective cohort
study designed to assess in patients the association between histologically
evaluated colon ischemia and plasma levels of endotoxin and d-lactate after
open aortic reconstruction.
Between February and April 2003, 12 consecutive patients underwent
aortic surgery; six had emergent procedures and six had elective aortic
surgery. Endotoxin and d-lactate levels were measured according to a
standardized protocol, and histologic samples of the colon were obtained by
sigmoidoscopy on days 4 to 6 after surgery or earlier, if clinically indicated.
Two hours postoperatively, elevated plasma levels of d-lactate were
found in patients with histologically proven ischemic colitis. Peak d-lactate
levels occurred on postoperative days 1 and 2. No alterations were noted in
plasma endotoxin in patients with or without ischemic colitis. Four patients
had histologically proven ischemic colitis: two died on postoperative day 3,
one died on postoperative day 31, and one patient was discharged home. All
episodes of ischemic colitis occurred in patients with ruptured abdominal
aortic aneurysms. Elevations in d-lactate level proceeded clinical decline
from colonic ischemia in the three patients who died.
Comment: Obviously, no definite conclusions can be made from this
small pilot study. However, the fact d-lactate levels were elevated in patients
with clinically important colonic ischemia before their clinical decline—and
were not elevated in patients without colonic ischemia—suggests a poten-
tially important role for this serum marker.
Plasma sphingomyelin in subclinical atherosclerosis: findings from the
multi-ethic study of atherosclerosis
Nelson JC, Jiang X-C, Tall A, et al. Am J Epidemiol 2006;163:903-12.
Conclusion: Plasma sphingomyelin is a component of the biologic
pathway mediating risk for subclinical atherosclerosis that is normally attrib-
utable to standard cardiovascular risk factors.
Summary: Plasma sphingomyelin is an independent risk factor for
coronary heart disease. In this study, the authors sought to determine the
relation of plasma sphingomyelin to subclinical atherosclerotic disease. The
relationship between plasma sphingomyelin and three different measure-
ments of subclinical cardiovascular disease (ankle and arm blood pressure
index, carotid intimal-medial thickness, and Agatston coronary artery and
calcium score) were assessed. Study subjects included 6814 asymptomatic
middle-aged adults from a multiethnic study of atherosclerosis first initiated
in 2000.
Plasma sphingomyelin levels correlated positively with lipid levels and
the Framingham risk score (P  .01 for both). The mean level of plasma
sphingomyelin was higher in women than men (50 16 mg/dL vs 45 15
mg/dL, P  .01). Plasma sphingomyelin levels were higher in never
(4916 mg/dL) vs current smokers (4517 mg/dL, P  .01). Levels of
subclinical vascular disease as assessed by all three measures were higher in
217
women with sphingomyelin levels of 60 mg/dL than in women with
sphingomyelin levels of 39 mg/dL. This association did not remain
significant after multivariant adjustment for standard cardiovascular risk
factors. Men with sphingomyelin levels of 60 mg/dL had higher calcium
scores (135 vs 99 Agatston units, P  .01) than men with sphingomyelin
levels 39 mg/dL.
Comment: Sphingomyelin accumulates in atheromas in animal models
and in human atheroma. Much sphingomyelin found in arteries arises from
synthesis within the arterial tissue (Circulation 1961;23:370-5). However,
synthesis of sphingomyelin within arterial tissue appears slow compared with
the total amount accumulated, suggesting plasma levels of sphingomyelin
may also contribute to accumulation of sphingomyelin within arterial tissue.
The unadjusted data from this study provide some support that plasma
sphingomyelin is a component of a pathway that mediates risk for subclinical
disease attributable to traditional cardiovascular risk factors.
Results of endovascular repair of the thoracic aorta with the Talent
Thoracic stent graft: the Talent Thoracic Retrospective Registry
Fattori R, Nienaber CA, Rousseau H, et al. J Thorac Cardiovasc Surg
2006;132:332-9.
Conclusion: The Talent thoracic stent graft appears effective in the
treatment of both acute and chronic diseases of the thoracic aorta.
Summary: This report derives from the Talent Thoracic Retrospective
Registry. It includes treatment of patients in seven major European referral
centers during an 8-year period. The Talent thoracic stent graft was used to
treat thoracic aortic pathology in 457 consecutive patients, of which 113
were emergent cases and 344 were elective. Median follow-up was 24  19
months (range, 1 to 85.1 months). Follow-up was based on clinical and
imaging findings. Adverse events were included, and all adverse events were
reviewed by a single physician.
In-hospital mortality was 5% (23 patients). Mortality was 8.5% during
follow-up of the 422 patients who survived the initial procedure. Thirty-six
patients died, and 11 of the deaths were related to aortic disease. Specific
procedure-related complications included stroke in 3.7%, paraplegia in 1.7%,
and local vascular access-site complications in 3.3%. Two patients died of
aortic rupture during placement of the device.
Persistent endoleak was documented in 64 cases, of which 43 demon-
strated primary endoleak present at the end of the procedure, and 21
endoleaks were discovered during follow-up. There were 7 patients with
persistent endoleak with aortic rupture during the follow-up period. Aortic
rupture associated with persistent endoleak occurred from 40 days to 35
months. All patients with aortic rupture associated with persistent endoleak
died. Stent graft migration occurred in seven cases, graft fabric failure in two,
and known modular disconnection in three. Survival was 90.97% at 1 year,
85.36% at 3 years, and 77.49% at 5 years. Freedom from a second procedure,
endovascular, or open conversion, at 1, 3 and 5 years was 92.41%, 81.3%,
and 70.0%, respectively.
Comment: These are registry data and are thus subject to all the limita-
tions of such data. Patients were treated for a variety of acute and chronic
conditions. Although patients were acquired during an 8-years period, only 95
patients had 3 years of clinical and imaging follow-up available. The data
suggest the Talent thoracic aortic stent graft can be deployed with a reasonable
rate of complications for a variety of thoracic aortic pathologies. Further
follow-up is obviously required to establish long-term efficacy.
A prospective analysis of fenestrated endovascular grafting: intermediate-
term outcomes
O’Neill S, Greenberg RK, Haddad F, et al. Eur J Vasc Endovasc Surg
2006;32:115-23.
Conclusion: Abdominal aortic stent grafts can be placed with graft
material incorporated around visceral arteries with effective prevention of
aneurysm rupture and minimal loss of visceral artery patency.
Summary: The study included patients with abdominal aortic aneu-
rysm (AAA) with short proximal necks who were considered high risk for
open repair and unacceptable for conventional endovascular repair. Fenes-
trated devices were individually designed from reconstructed computed
tomography (CT) data using the Cook Zenith graft as the device platform.
The design of each graft required knowledge of the ostial diameter of each
visceral vessel, relative distances from a fixed landmark (usually the superior
mesenteric artery), and radial orientation of the visceral ostial. Small fenes-
trations were placed between stent struts and could be used in conjunction
with a visceral artery stent. Larger fenestrations (8 to 12 mm in diameter)
could be placed with a stent strut crossing an ostium and were not intended
for use with visceral artery stents. Scalped fenestrations, hemi-oval in shape,
were in the most proximal portion of the fabric. Patients were followed-up
with CT scan, duplex ultrasound imaging, and plain abdominal radiographs
at hospital discharge, at 1, 6 and 12 months, and then annually thereafter.
Between 2001 and 2005, 119 patients were treated. Their mean age
was 75 years, and the mean aneurysm size was 65 mm. There were 302
visceral vessels inferior to the fabric seal, with a mean of 2.5 vessels per
patient. Fifty-eight percent of the grafts incorporated two venal arteries and
the superior mesenteric artery. There was no acute visceral artery loss at the
time of the graft implantation. Mean follow-up was 19 months (range, 0 to
42 months). One death occurred30 days of device implantation. Survival
by Kaplan-Meier analysis at 1, 12, 24, and 36 months was 99%, 92%, 83%,
and 79%, respectively. There were no conversions, and no known aneurysm
ruptures have occurred. There were 11 type 1 endoleaks at discharge. The
endoleak rate was 10% at 30 days, and all were type 2. At 2 years, fenestra-
tions had decreased 5 mm in diameter in 77% of cases. During follow-up,
10 of 231 renal artery stents occluded, with three occlusions before dis-
charge. There were 12 additional renal artery stent stenoses. Three patients
had permanent dialysis.
Comment:Outside of a few selected centers, progress has been slow in
the development of fenestrated endovascular grafts. This is likely because the
grafts must be individually designed and a high level of technical skill is
required for successful placement. Acceptance of this technology will also
require conclusive evidence that the graft body itself does not migrate. As
pointed out by the authors, even minimum migration of a fenestrated graft
will result in significant renal and mesenteric artery complications.
Endarterectomy versus stenting in patients with symptomatic severe
carotid stenosis
Mas J-L, Chatellier G, Beyssen B; and the EVA-3S Investigators. New Engl
J Med 2006;355:1660-71.
Conclusion: Compared with carotid artery stenting (CAS), carotid
endarterectomy (CEA) in patients with symptomatic carotid stenosis of
60% to 99% provides lower rates of stroke and death at 1 and 6 months.
Summary:This was a randomized, publicly funded, noninferiority trial
conducted in 10 nonacademic and 20 academic medical centers in France.
Eligible for the trial were patients with symptomatic carotid stenosis, defined
as retinal or hemispheric transient ischemic attacks or a nondisabling stroke
occurring 120 days from study enrollment, and who had 60% to 99%
carotid stenosis. Confirmation of stenosis was by contrast angiography or a
combination of duplex scanning and magnetic resonance angiography.
Patients had to be suitable candidates for either CEA or CAS. All evaluations
were performed by neurologists at 48 hours, 30 days, and 6 months after
treatment, and every 6 months thereafter. The primary end point was stroke
or death 30 days of treatment.
The Data Safety and Monitoring Committee stopped this trial after
inclusion of 527 patients for reasons of both safety and futility. The 30-day
incidence of any stroke or death after CEA was 3.9% (95% confidence
interval [CI], 2.0% to 7.2%). After stenting, the 30-day incidence of stroke or
death was 9.6% (95% CI, 6.4% to 14.0%). The relative risk of any stroke or
death after stenting was 2.5 times that of CEA (95% CI, 1.2 to 5.1). There
was a 1.5% incidence of disabling stroke after CEA (95% CI, 0.5% to 4.2%)
and a 3.4% incidence of disabling stroke after CAS (95% CI, 1.7% to 6.7%).
The relative risk of disabling stroke in stented patients vs patients undergo-
ing CEA was 2.2 (95% CI, 0.7 to 7.2). The incidence of any stroke or death
6months was 6.1% after CEA and 11.7% after stenting (P .02). CAS had
more local major complications, and CEA had more systemic major compli-
cations (mainly pulmonary). Differences were not significant. Cranial nerve
injury was more common after CEA than after CAS.
Comment: This was a publicly funded, prospective, randomized trial.
It has the great benefit of not being tainted by industry sponsorship. There
was a lower-than-predicted stroke and death rate for CEA and a higher-than-
predicted stroke and death rate for CAS. A criticism of the trial will obviously
be a possible learning curve effect in the stented patients and the continuing
evolving of CAS techniques and devices. This study is far cleaner than the
SAPPHIRE trial (New Engl J Med 2004;351:1493-501) that was used to
generate United States Food and Drug Administration approval of CAS for
symptomatic high-risk patients. At the very least, the current trial raises
serious concern about the relative safety of CAS in symptomatic patients of
standard surgical risk. Given current data, it remains that the only patients
who should undergo CAS outside of a clinical trial are very high-risk patients
with symptomatic stenosis. Determination of high surgical risk should be by
a multidisciplinary team that is able to evaluate perioperative systemic and
surgical risk. It is not acceptable or ethical for high surgical risk to be
determined by individuals who are only capable of performing carotid stents
or who have financial incentives to participate in industry-sponsored trials.
D-dimer testing to determine the duration of anticoagulation therapy
Palareti G, Cosmi B, Legnani C, and the PROLONG Investigators. N Engl
J Med 2006;355:1780-9.
Conclusion: An abnormal D-dimer level 1 month after discontinua-
tion of anticoagulation for a first time episode of venous thromboembolism
(VTE) is a marker for increased risk of VTE recurrence that can be reduced
by reinstituting anticoagulation.
Summary: There is a trend towards individualization of duration of
anticoagulation for VTE. Patients are now stratified to whether the VTE
episode was provoked, such as after trauma or surgery or another known risk
JOURNAL OF VASCULAR SURGERY
January 2007218 Abstracts
